프로테오믹스 시장 예측(-2030년) : 제품별, 서비스 및 소프트웨어별, 기술별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Proteomics Market is accounted for $52.28 billion in 2023 and is expected to reach $115.57 billion by 2030 growing at a CAGR of 12.0% during the forecast period. The branch of biotechnology known as proteomics is defined as the application of molecular biology, biochemistry, and genetics techniques to the examination of the structure, function, and interactions of the proteins made by a specific cell, tissue, or organism, the organization of the information in databases, and the applications of the data. Proteomics can be categorized into a number of different subcategories, including structural, functional, and expression proteomics. Proteomics enables the identification of ever-increasing numbers of proteins. This varies with time and distinct requirements, or stresses, that a cell or organism undergoes.

According to Globocan, in December 2020, there were 19.3 million new cases of cancer across the world and 10 million cancer-related deaths were reported. Similarly, CVDs are one of the major causes of death worldwide. For instance, as per the WHO (2021), target diseases kill 41 million patients per year.

Market Dynamics:

Driver:

Rising use of nano proteomics and increasing prevalence of chronic illnesses

Many proteomics applications have been linked to nanotechnology, including phosphoproteomics/metal oxide nanoparticles, nanostructured surfaces for protein separation, and array techniques for analytical detection of biomarker proteins. Nanoproteomics has emerged as a field of study as a result of the application of proteomics techniques to nanotechnology. Through numerous nanotechnology applications, including nanoporous structures, functionalized nanoparticles, quantum dots, and polymeric nanostructures, this technique is used as a supporting element to revolutionize proteomics. Thus, the need for personalized therapies, along with the prevalence of life-threatening diseases, is anticipated to benefit the industry throughout the forecast period.

Restraint:

High cost of instruments and reagents

Companies obtain substances that either stimulate or inhibit target proteins using publicly available structural data and trial-and-error techniques. The study of protein structure necessitates the use of high-throughput equipment. Gene cloning, protein expression, protein purification, and protein crystallization are all frequently done in proteomics using X-ray crystallography. These processes all require a significant amount of laboratory time, which drives up the price of testing each sample. Moreover, developing nations struggle to enter the proteomics field due to the high cost of equipment and supplies. Such factors are anticipated to impede market expansion.

Opportunity:

Technological Progress in Proteomics

Technological advances that have greatly increased sensitivity and resolution, permitted high-throughput and multiplexed analysis, facilitated data integration, improved sample preparation and fractionation techniques, permitted mass spectrometry-based imaging, and provided sophisticated data analysis and informatics tools have revolutionized the field of proteomics. By enabling a complete and thorough understanding of the proteome, these developments have been crucial in fostering the market's expansion. Additionally, these technological developments have increased the scope of proteomics research, allowing thorough and in-depth investigation of proteins in a variety of biological contexts, which is fueling market expansion.

Threat:

Technological complexities and lack of standardization

Proteomics market growth may be hampered by technological complexity, data analysis difficulties, and standardization issues. Complex technologies and methodologies used in proteomics research call for specialized knowledge and skills. Proteomic data analysis and result interpretation can be difficult and require expertise in bioinformatics and data analysis. The analysis and interpretation of the enormous amounts of data produced by proteomics experiments can be challenging. Additionally, there may be difficulties and barriers to the market's expansion due to a lack of standardization practices and the requirement for strong data analysis pipelines.

COVID-19 Impact:

The proteomics services have shown to benefit from the COVID-19 pandemic, which has accelerated market growth. A number of businesses were observed to reduce their R&D expenditures for clinical trials in contrast to earlier expenditures, indicating the extent of the pandemic's impact. Additionally, due to the rise of novel clinical trial methodologies or models, which include the use of technologically advanced mass spectrometers by CROs specifically for quality outcomes, rapid clinical trials have been reported. The proteomics industry has strong development opportunities as an outcome of these traits.

The drug discovery segment is expected to be the largest during the forecast period

The drug discovery segment is estimated to be the largest during the extrapolated period. The expansion of this industry can be attributed to the development of structure-based drug design, a greater focus on developing personalized medicines, and increased funding in these fields. Additionally, proteomics technologies also provide a mechanism to demonstrate a medicine's potential early in the drug discovery process, saving pharmaceutical companies a large sum of money and ultimately assisting patients and healthcare systems, which support the segment's expansion.

The Spectroscopy segment is expected to have the highest CAGR during the forecast period

Spectroscopy segment is anticipated to have highest CAGR during the projected period. Proteomics research relies primarily on spectroscopy, which is also commonly used for analyzing proteins and their structural properties. It makes it possible to recognize, measure, and characterize proteins, providing essential details about their roles, interactions, and changes. Additionally, continuous advancements in spectroscopy technologies and data analysis tools are further expanding the capabilities and applications of spectroscopy in the proteomics market.

Region with largest share:

Asia-Pacific is anticipated to have largest share during the forecast period. The expansion of the proteomics industry in this area is due to the presence of pharmaceutical businesses there as well as the rising elderly population in nations like China and India. Additionally, as demand for personalized medicine rises, so does the need for drug discovery and developments in the biotechnology industry fuel market expansion in the region. The Asia-Pacific area has the largest pharmaceutical sector, and a wealth of technologically advanced medical devices that may be easily accessed by producers of proteomics-based goods.

Region with highest CAGR:

North America commanded highest CAGR throughout the domination period due to the development of structure-based drug design, expansion of omics research, desire for high-quality research tools for data reproducibility, and focus on the creation of personalized treatments. Partnerships and collaborations among significant businesses in this region are also helping to expand this industry. Furthermore, in order to accelerate the characterisation and quality monitoring of complex therapeutic proteins, Thermo Fisher Scientific Inc. and Symphogen developed a proven platform process.

Key players in the market:

Some of the key players in Proteomics Market include: Agilent Technologies, inc., Illumina, Inc., Ge Healthcare, Bio - Rad Laboratories, Inc., Bruker Corporation, Thermo fisher Scientific, Inc., Promega Corporation , F.Hoffmann-La Roche Ltd., Danaher, Merck Kgaa., Waters Corporation, Caprion Proteomics Inc., Luminex Corporation, PerkinElmer, Inc., SomaLogic Operating Co. and Olink.

Key Developments:

In February 2023, Waters Corporation acquired Wyatt Technology, which enhances the portfolio of Separation and Detection, which provides customers with an unmatched set of analytical solutions across a wide range of applications.

In October 2022, Agilent Technologies Inc. and CMP Scientific Corp. entered into a co-marketing agreement to provide an integrated capillary electrophoresis-mass spectrometry (CE-MS) solution for the life science and pharmaceutical industries.

In August 2022, Bruker Corporation introduced the new nano Elute 2 nano-LC, MetaboScape, and TASQ software to promote the study of protein-protein interaction and metaproteomics applications. These products also support fluxomics and the most recent developments in PaSER intelligent acquisition.

Products Covered:

• Reagents & Consumables
• Instruments
• Services

Services & Softwares Covered:

• Core Proteomics Services
• Bioinformatics Services & Software

Technologies Covered:

• Spectroscopy
• Chromatography
• Electrophoresis
• Protein Microarrays
• X-Ray Crystallography
• Surface Plasmon Resonance
• Protein Fractionation
• Other Technologies

Applications Covered:

• Clinical Diagnosis
• Clinical Research
• Drug Discovery
• Other Applications

End Users Covered:

• Laboratories
• Academic & Research Institute
• Hospitals
• Pharmaceutical & Biopharmaceutical Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Proteomics Market, By Product

• 5.1 Introduction
• 5.2 Reagents & Consumables
• 5.3 Instruments
• 5.4 Services

6 Global Proteomics Market, By Services & Software

• 6.1 Introduction
• 6.2 Core Proteomics Services
  • 6.2.1 Protein Characterization Services
  • 6.2.2 Protein Identification Services
  • 6.2.3 Protein Purification Services
  • 6.2.4 Quantitative Proteomics Services
  • 6.2.5 Protein Seqencing Services
  • 6.2.6 Protein Separation Services
  • 6.2.7 Custom Assay Services
• 6.3 Bioinformatics Services & Software
  • 6.3.1 Bioinformatics Tools
  • 6.3.2 Bioinformatics Services
  • 6.3.3 Bioinformatics Databases

7 Global Proteomics Market, By Technology

• 7.1 Introduction
• 7.2 Spectroscopy
  • 7.2.1 Mass Spectroscopy
• 72.2 Nuclear Magnetic Resonance Spectroscopy
  • 7.2.2 Circular Dichroism Spectroscopy
• 7.3 Chromatography
  • 7.3.1 High Performance Liquid Chromatography
  • 7.3.2 Supercritical Fluid Chromatography
  • 7.3.3 Affinity Chromatography
  • 7.3.4 Ion Chromatography
• 7.4 Electrophoresis
  • 7.4.1 Gel Electrophoresis
  • 7.4.2 Capillary Electrophoresis
• 7.5 Protein Microarrays
  • 7.5.1 Biochips
    • 7.5.1.1 Lab-On-Chips
    • 7.5.1.2 Protein Chips
  • 7.5.2 Microarray Instruments
    • 7.5.2.1 Integrated Systems
    • 7.5.2.2 Arrayers
    • 7.5.2.3 Microarray Scanners
• 7.6 X-Ray Crystallography
• 7.7 Surface Plasmon Resonance
• 7.8 Protein Fractionation
• 7.9 Other Technologies

8 Global Proteomics Market, By Application

• 8.1 Introduction
• 8.2 Clinical Diagnosis
  • 8.2.1 Infectious Diseases
  • 8.2.2 Cancer
  • 8.2.3 Diabetes
  • 8.2.4 Autoimmune Diseases
  • 8.2.5 Neurological Disorders
  • 8.2.6 Cardiovascular Diseases
  • 8.2.7 Other Clinical Diagnostic Application
• 8.3 Clinical Research
• 8.4 Drug Discovery
  • 8.4.1 Target Discovery
  • 8.4.2 Lead Optimization
  • 8.4.3 Lead Identification
  • 8.4.4 Preclinical Studies
• 8.5 Other Applications

9 Global Proteomics Market, By End User

• 9.1 Introduction
• 9.2 Laboratories
• 9.3 Academic & Research Institute
• 9.4 Hospitals
• 9.5 Pharmaceutical & Biopharmaceutical Companies
• 9.6 Other End Users

10 Global Proteomics Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Agilent Technologies, inc.
• 12.2 Illumina, Inc.
• 12.3 Ge Healthcare
• 12.4 Bio - Rad Laboratories, Inc.
• 12.5 Bruker Corporation
• 12.6 Thermo fisher Scientific, Inc.
• 12.7 Promega Corporation
• 12.8 F. Hoffmann-La Roche Ltd.
• 12.9 Danaher
• 12.10 Merck Kgaa.
• 12.11 Waters Corporation
• 12.12 Caprion Proteomics Inc.
• 12.13 Luminex Corporation
• 12.14 PerkinElmer, Inc.
• 12.15 SomaLogic Operating Co.
• 12.16 Olink